NetworkNewsBreaks – BriaCell Therapeutics Corp. (TSX.V: BCT) (OTCQB: BCTXF) Lead Clinical Candidate Development Advances Following Promising Phase IIa Results
Clinical-stage biotechnology company BriaCell Therapeutics (TSX.V: BCT) (OTCQB: BCTXF) has achieved proof of concept and recently reported promising results from its Phase IIa study of its lead clinical candidate, Bria-IMT. An article further discussing the company reads, “A total of 31 patients with advanced stage breast cancer were enrolled in the Phase II Bria-IMT monotherapy study. The proof of concept and mechanism of action work is based on the results observed in the first 20 patients, while assessment of the remaining 11 patients is still in progress. …The preliminary data seems to confirm the company’s HLA Matching Hypothesis and support…







